Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Quarterly Earnings Results, Misses Expectations By $3.54 EPS

Tonix Pharmaceuticals (NASDAQ:TNXP) released its quarterly earnings results on Tuesday. The company reported ($9.77) earnings per share for the quarter, missing the consensus estimate of ($6.23) by ($3.54), Zacks reports. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%.

Tonix Pharmaceuticals Stock Up 26.1 %

Shares of NASDAQ TNXP traded up $4.25 during mid-day trading on Tuesday, reaching $20.53. 2,548,600 shares of the company were exchanged, compared to its average volume of 625,432. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The stock has a market cap of $38.37 million, a price-to-earnings ratio of 0.00 and a beta of 2.23. Tonix Pharmaceuticals has a 1 year low of $6.76 and a 1 year high of $1,193.28. The firm has a 50-day moving average of $19.04 and a 200 day moving average of $19.79.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research report on Monday, February 10th. They issued a “sell” rating on the stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.